Document is current
Any future updates will be listed below
-
Authors
Scheele, Colinda L. G. J. https://orcid.org/0000-0001-8999-5451
Herrmann, David https://orcid.org/0000-0002-9514-7501
Yamashita, Erika
Lo Celso, Cristina
Jenne, Craig N.
Oktay, Maja H.
Entenberg, David https://orcid.org/0000-0003-0422-7264
Friedl, Peter
Weigert, Roberto
Meijboom, Franck L. B.
Ishii, Masaru
Timpson, Paul https://orcid.org/0000-0002-5514-7080
van Rheenen, Jacco https://orcid.org/0000-0001-8175-1647
- License Information
-
More Information
Article History
Accepted: 12 September 2022
First Online: 10 November 2022
Competing interests
: P.T. receives reagents from Kadmon, InxMed (also consultant), Redx Pharma, Équilibre Biopharmaceuticals and Amplia Therapeutics. Under a licensing agreement between Amplia Therapeutics and Garvan Institute of Medical Research, D.H. and P.T. (consultant) are entitled to milestone payments. All other authors declare no competing interests.
